Sagimet Share Price

Sagimet Share Price

NASDAQ: SGMT | Small Cap | Healthcare
$10.17
+$0.33 (3.35%) Last updated on 19 Nov, 2026 | 01:27 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Sagimet Stock Performance

Open
$9.86
Prev. Close
$9.84
Circuit Range
N/A
Day Range
$9.86 - $10.27
Year Range
$4.51 - $11.44
Volume
71,222
Average Traded
$10.11

Sagimet Share Price Today

As of 19 November 2026, Sagimet Biosciences Inc. Series A's share price is $10.17. The stock opened at $9.86, compared to its previous close of $9.84. During today's trading session, Sagimet Biosciences Inc. Series A's share price traded between $9.86 and $10.27, with an average price of $10.06. Over the past 52 weeks, the stock has recorded a high of $11.44 and a low of $4.51. In terms of performance, Sagimet Biosciences Inc. Series A's share price has risen by 39.32% over the last six months and is up 40.66% on a year-on-year basis.

Sagimet Share Price Chart

Line chart of the Sagimet price trend over the selected period. The price rose overall, ranging from 9.86 to 10.29, ending at 10.17.
$9.86$10.27
L
Show Current Price
H

Sagimet Stock Fundamentals & Key Indicators

Market Cap
$328.95M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.74
Revenue (TTM)
$0.00
Return On Equity (TTM)
-22.02%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-100.10%

Sagimet Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$9.57-$10.65-$13.95-$19.15
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-11.29%-30.99%-37.28%

Sagimet Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$2.00$0.00$0.00
Net Profit-$27.88-$45.57-$51.04
Net Profit Margin-1394.00%N/AN/A
Income ChangeN/A-63.45%-12.00%

Sagimet Balance Sheet

All figures in USD Million

Particulars202520242023
Non Current Assets0.087.490.07
Current Assets116.4152.7796.65
Total Assets116.48160.2696.72
Non Current Liabilities0.00.00.0
Current Liabilities5.14.455.65
Total Liabilities5.14.455.65
Shareholders' Equity111.38155.8191.07

Sagimet Cash Flow

Annually

All figures in USD Million

Particulars202520242023
Operating-45.65-42.44-23.77
Investing4.56-61.6812.58
Financing0.28104.8286.17

About Sagimet

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Sagimet Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$9.92
$10.18
+2.62%
Oct 2026
$9.74
$9.91
-0.90%
Sep 2026
$10.31
$10.01
-6.84%
Aug 2026
$6.69
$10.74
+50.84%
Jul 2026
$7.88
$7.12
-7.89%
Jun 2026
$7.22
$7.73
+5.89%
May 2026
$8.17
$7.30
-9.54%
Apr 2026
$5.19
$8.07
+54.30%
Mar 2026
$5.64
$5.23
-8.57%
Feb 2026
$5.80
$5.72
+1.06%
Jan 2026
$5.94
$5.66
-4.39%
Dec 2025
$6.99
$5.92
-18.12%

Sagimet Share Price FAQs